Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Interim Analyses from the Beacon Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria

Gayle Ross, Peter Stewart, George Mensing, Melanie Chin, Haley Howell, Heidi Mangus, William Savage

Blood (2023) 142 (Supplement 1): 923.

https://doi.org/10.1182/blood-2023-175011

Published: 2023

Journal Articles

Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design

George Mensing, Haley Howell, Katherine Chan, Brian MacDonald, Will Savage

Blood (2022) 140 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2022-157810

Published: 2022

Journal Articles

DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers

Natasha Novikov, Akshay Buch, Hua Yang, Sarah Tuller, Michelle Andruk, Katherine Chan, Min Wu, Richard Rodriguez, Rajiv Panwar, Haley Howell, Brian MacDonald, Will Savage

Blood (2022) 140 (Supplement 1): 5339–5340.

https://doi.org/10.1182/blood-2022-167870

Published: 2022

Journal Articles

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Kevin A. Goncalves, PhD, Sharon L. Hyzy, MS, Katelyn J. Hammond, BS, Patrick C. Falahee, PhD, Haley Howell, BS, BA, Jan Pinkas, PhD, Veit Schmelmer, PhD, Jonathan G. Hoggatt, PhD, David T. Scadden, MD, Steven M Devine, MD, John F. DiPersio, MD PhD, Will J. Savage, MDPhD, John C. Davis, Jr., MD MPH, MS

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142804

Published: 2020

Journal Articles

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

John F. DiPersio, MD PhD, Jonathan Hoggatt, PhD, Steven Devine, MD, Lukasz Biernat, MD, Haley Howell, BS, BA, Veit Schmelmer, PhD, Jason R. Neale, PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Kevin A. Goncalves, PhD, Glen D. Raffel, MD PhD, Patrick C. Falahee, PhD, Dwight M. Morrow, PhD, John C. Davis, Jr., MD MPH, MS

Blood (2019) 134 (Supplement_1): 1961.

https://doi.org/10.1182/blood-2019-127523

Published: 2019

NARROW

Interim Analyses from the Beacon Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria

Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design

DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Email alerts

ASH Publications

American Society of Hematology

Interim Analyses from the Beacon Trial: A Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria

Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design

DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers

Mgta-145, in Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant

Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of Mgta-145 Alone or in Combination with Plerixafor

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only